Candel Therapeutics (CADL) vs ProKidney (PROK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Candel Therapeutics (CADL) has outperformed ProKidney (PROK) over the past year, gaining 53.3% versus a loss of 49.1%. Over five years, CADL leads with a -1.7% price change compared with -83.2% for PROK. Candel Therapeutics is the larger company by market cap ($755.2 million vs $692.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | PROK |
|---|---|---|
| Share price | $9.87 | $1.74 |
| Market cap | $755.24M | $692.58M |
| 1-day change | +2.17% | +4.52% |
| YTD return | +70.97% | -25.89% |
| 1-year return | +53.33% | -49.08% |
| 5-year return | -1.73% | -83.18% |
| EPS (TTM) | $-1.46 | $-0.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $3.48 |
| 52-week low | $4.35 | $1.30 |
| Distance from 52-week high | -29.50% | -50.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +120.36% | +260.23% |
| Average volume | 1.21M | 1.30M |
| Shares outstanding | 76.52M | 208.93M |
| Employees | 55 | 231 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed PROK by 102.4 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About ProKidney
PROK stock →ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 231 employees
CADL vs PROK FAQ
Which is bigger, Candel Therapeutics or ProKidney?
Candel Therapeutics (CADL) is larger, with a market capitalization of $755.24M compared with $692.58M for ProKidney (PROK).
Which stock has performed better over the past year, CADL or PROK?
CADL returned +53.33% over the past 12 months, compared with -49.08% for PROK (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and ProKidney in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.